CIK 0001681087
- Non-accelerated filer
- Smaller reporting company
Tectonic Therapeutic, Inc.
Sign in to watch- Ticker
- TECX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- NY
- Entity type
- Operating
- EIN
- 810710585
- Phone
- +1 339-666-3320
- Business address
- 490 ARSENAL WAY, SUITE 200, WATERTOWN, MA
- Former names
- AvroBio, Inc., AVROBIO, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,920
- in 2 filings, $14K under 10b5-1 plans
Net −$13,920. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-04-05 | MACKAY GEOFFREY | Sale | −13,302 | $27.26 | $363K | 410,221 |
| 2019-03-05 | MACKAY GEOFFREY | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2019-01-16 | SVLSF VI, LLC 10% owner | Other disposition | −778,663 | 1,866,791 | ||
| 2019-01-16 | SVLSF VI, LLC 10% owner | Other disposition | −26,660 | 63,913 | ||
| 2019-01-07 | Vickers Philip J. Director | Grant or award · Stock Option (Right to Buy) | +18,743 | 18,743 | ||
| 2019-01-02 | Avruch Steven VP & General Counsel | Grant or award · Stock Option (Right to Buy) | +88,636 | 88,636 | ||
| 2019-01-02 | Ostrowski Erik Chief Financial Officer | Grant or award | +2,300 | 2,300 | ||
| 2019-01-02 | Ostrowski Erik Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +186,000 | 186,000 | ||
| 2018-12-17 | Volck Birgitte President of R&D | Grant or award · Stock Option (Right to Buy) | +293,000 | 293,000 | ||
| 2018-10-08 | Dorton Katina Chief Financial Officer | Exercise or conversion | +10,000 | $0.91 | $9K | 10,000 |
| 2018-10-08 | Dorton Katina Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) | −10,000 | 148,318 | ||
| 2018-10-08 | KREHER NERISSA Chief Medical Officer | Exercise or conversion | +2,942 | $0.91 | $3K | 2,942 |
| 2018-10-08 | KREHER NERISSA Chief Medical Officer | Exercise or conversion · Stock Option (Right to Buy) | −2,942 | 24,629 | ||
| 2018-06-25 | Atlas Venture Fund X, L.P. 10% owner | Conversion | +806,711 | 806,711 | ||
| 2018-06-25 | Atlas Venture Fund X, L.P. 10% owner | Conversion | +3,044,579 | 3,851,290 | ||
| 2018-06-25 | Atlas Venture Fund X, L.P. 10% owner | Conversion | +905,188 | 4,756,478 | ||
| 2018-06-25 | Atlas Venture Fund X, L.P. 10% owner | Conversion · Series Seed Preferred Stock | −3,333,333 | 0 | ||
| 2018-06-25 | Atlas Venture Fund X, L.P. 10% owner | Conversion · Series A Preferred Stock | −12,580,199 | 0 | ||
| 2018-06-25 | Atlas Venture Fund X, L.P. 10% owner | Conversion · Series B Preferred Stock | −3,740,239 | 0 | ||
| 2018-06-25 | Requadt Scott Director | Conversion | +2,283,434 | 2,283,434 |
Page 15 of 17 · 322 trades